PET/MRI with FDG for Head Neck Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Head Neck Cancer+1 More
PET/MRI with FDG - Radiation
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is investigating whether or not using quantitative diffusion MRI (dMRI) is a feasible way to get an accurate and comprehensive assessment of treatment response in tumors.

Eligible Conditions
  • Head Neck Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Head Neck Cancer

Study Objectives

3 Primary · 1 Secondary · Reporting Duration: 2 Years Post-Treatment

2 Years Post-Treatment
Progression-Free Survival (PFS)
6 weeks
Intra-class Correlation (ICC)
Intra-subject Coefficient of Variation (CV)
Overall Response Rate (ORR)

Trial Safety

Safety Progress

1 of 3

Other trials for Head Neck Cancer

Trial Design

2 Treatment Groups

Optimization of Techniques
1 of 2
: Longitudinal Monitoring
1 of 2
Experimental Treatment

3 Total Participants · 2 Treatment Groups

Primary Treatment: PET/MRI with FDG · No Placebo Group · N/A

Optimization of TechniquesExperimental Group · 2 Interventions: MRI scan without contrast, PET/MRI with FDG · Intervention Types: Radiation, Radiation
: Longitudinal MonitoringExperimental Group · 2 Interventions: MRI scan without contrast, MRI with gadolinium · Intervention Types: Radiation, Radiation

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years post-treatment

Who is running the clinical trial?

NYU Langone HealthLead Sponsor
1,250 Previous Clinical Trials
743,735 Total Patients Enrolled
Elcin Zan, MDPrincipal InvestigatorNYU Langone

Eligibility Criteria

Age 18+ · All Participants · 7 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are a treatment-naïve patient with metastatic lymph nodes prior to surgery or chemoradiation therapy.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 18th, 2021

Last Reviewed: October 25th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.